Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Capital Expenditures: 2012-2025

Historic Capital Expenditures for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $2.8 million.

  • Veracyte's Capital Expenditures rose 24.53% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 4.10%. This contributed to the annual value of $11.3 million for FY2024, which is 13.31% up from last year.
  • As of Q3 2025, Veracyte's Capital Expenditures stood at $2.8 million, which was up 117.11% from $1.3 million recorded in Q2 2025.
  • Veracyte's 5-year Capital Expenditures high stood at $4.1 million for Q4 2024, and its period low was $841,000 during Q4 2021.
  • For the 3-year period, Veracyte's Capital Expenditures averaged around $2.5 million, with its median value being $2.5 million (2023).
  • As far as peak fluctuations go, Veracyte's Capital Expenditures soared by 185.35% in 2021, and later crashed by 53.57% in 2025.
  • Veracyte's Capital Expenditures (Quarterly) stood at $841,000 in 2021, then surged by 122.59% to $1.9 million in 2022, then spiked by 33.39% to $2.5 million in 2023, then spiked by 65.84% to $4.1 million in 2024, then climbed by 24.53% to $2.8 million in 2025.
  • Its Capital Expenditures was $2.8 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.8 million in Q1 2025.